Teresa Novak
Medical · Lincoln, NENPI 1487606463
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 27.5% of the total. Reporting peaked in 2021 at $1,891 and has fallen 91.9% since, to $154 in 2025.
Across 203 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$821
- Novo Nordisk$277
- Amgen$224
- Lilly USA, LLC$205
- AstraZeneca$194
- GSK$146
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,988100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $821 |
| Novo Nordisk | 15 | $277 |
| Amgen | 15 | $224 |
| Lilly USA, LLC | 21 | $205 |
| AstraZeneca | 8 | $194 |
| GSK | 18 | $146 |
| Kowa Pharmaceuticals America, Inc. | 12 | $144 |
| Boehringer Ingelheim | 10 | $117 |
| Biohaven Pharmaceuticals, Inc. | 5 | $88 |
| Inari Medical, Inc. | 2 | $86 |
| Pfizer | 5 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Bayer | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 3 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Merck | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Biogen | 1 | $23 |
| Optinose US, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$100
How this compares
$2,988 in reported general payments places this provider in the 80th percentile of 216 medical providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ViberziEluxadoline | 12 | $18,335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieViberzi | $821 | $18,33512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 216 medical providers in Nebraska.
Other medical in Lincoln
- Michelle SitzmanLincoln$206K
- Kaitlin MatthesLincoln$98K
- Jay ArthurLincoln$8K
- Emma EdwardsLincoln$8K
- Erin HeggeLincoln$7K
- Christine TrombinoLincoln$5K
- Samantha PedersonLincoln$5K
- Sheri JohnsonLincoln$5K
- Kerri OttoLincoln$5K
- Mason BeelLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.